Uniunea Europeană - română - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - sânii neoplasme - agenți antineoplazici - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Uniunea Europeană - română - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresoare - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

f.hoffmann-la roche, ltd. - pertuzumabum + trastuzumabum - soluţie injectabilă - 600 mg/600 mg/10 ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

f.hoffmann-la roche, ltd. - pertuzumabum + trastuzumabum - soluţie injectabilă - 1200 mg/600 mg/15 ml

Uniunea Europeană - română - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

f.hoffmann-la roche ltd - obinutuzumabum - concentrat pentru soluţie perfuzabilă - 1000 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

f.hoffmann-la roche, ltd. - polatuzumab vedotin - pulbere pentru concentrat pentru soluţie perfuzabilă - 30 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

f.hoffmann-la roche, ltd. - polatuzumab vedotin - pulbere pentru concentrat pentru soluţie perfuzabilă - 140 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

f.hoffmann-la roche, ltd. - ocrelizumab - concentrat pentru soluţie perfuzabilă - 30 mg/ml

Uniunea Europeană - română - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - agenți antineoplazici - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.